Saroglitazar, a dual proliferator-activated receptor (PPAR)-α/γ agonist, shows promising effects in managing dyslipidemia and glycemic abnormalities; however, real-world evidence (RWE) is limited across varying degrees of renal function. The gene discussed is PPARA; the disease is metabolic syndrome.